Clinical trials: Acute Ischaemic Stroke
Acute Ischemic Stroke
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to…
- Trial name
- NCT06129175
- Testing
- Neuroncell-EX
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Cytopeutics Sdn. Bhd.
Stroke, Acute
An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)
RGTA® (ReGeneraTing Agent) are synthetic polysaccharides mimicking extra-cellular matrix scaffold elements and protective agents called Heparan Sulphates (HSPGs). OTR4132-MD is provided as a sterile injectable medical device.
- Trial name
- MATRISS (NCT04083001)
- Testing
- OTR4132MD
- Where
- 3 sites in France
- Volunteers
- 19 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Ischemic Stroke
Efficacy and Safety of Mexidol® in Stroke Therapy
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo.
- Trial name
- MIR (NCT06437626)
- Testing
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Where
- 17 sites in Kazakhstan, Russia and 1 more
- Volunteers
- 304 people
- Sponsor
- Pharmasoft
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Acute Ischemic Stroke
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Post-Market Registry
- Trial name
- RECANOVA (NCT07599904)
- Testing
- Mechanical Thrombectomy
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Acute Ischemic Stroke
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
- Trial name
- NCT05993884
- Testing
- iEPCs
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Stroke, Acute
THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA
The purpose of this study is to test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".
- Trial name
- NCT01957774
- Testing
- THR-18
- Where
- Ukraine
- Volunteers
- 30 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Ischemic Stroke
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
- Trial name
- ReMEDy1 (NCT03290560)
- Testing
- Recombinant human tissue kallikrein
- Where
- 12 sites in Australia
- Volunteers
- 92 people
- Sponsor
- DiaMedica Therapeutics Inc
Ischemic Stroke
REperfusion With Cooling in CerebraL Acute IscheMia II
The primary objective of this study is to determine the feasibility and safety of achieving rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for patients experiencing acute ischemic stroke due…
- Trial name
- RECCLAIM-II (NCT03804060)
- Testing
- Thermogard XP3, Recanalization only
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- ZOLL Circulation, Inc., USA
Acute Ischemic Stroke
Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours.
- Trial name
- NCT03198715
- Testing
- DS1040b
- Where
- 20 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24B (NCT00826059)
- Testing
- Active Sphenopalatine Ganglion (SPG) Stimulation
- Where
- 73 sites in United States, Canada and 16 more
- Volunteers
- 1,078 people
- Sponsor
- BrainsGate
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
- Trial name
- NCT06707987
- Testing
- Non-immunogenic staphylokinase
- Where
- Russia
- Volunteers
- 23,250 people
- Sponsor
- Supergene, LLC
Acute Ischemic Stroke
ANAIS Study to Confirm the Safety and Performance of the ANA 5F Advanced Neurovascular Access®
Prospective, single-arm, multi-center study to assess the safety and performance of the ANA 5F Advanced Neurovascular Access®, in combination with a stent retriever in patients with acute ischemic stroke.
- Trial name
- ANAIS (NCT05409430)
- Testing
- Neurothrombectomy
- Where
- 3 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Anaconda Biomed S.L.
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.
- Trial name
- NCT06388772
- Testing
- QHRD106 Injection
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
AIS
NBP in Adult Patients With Acute Ischemic Stroke (AIS)
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.
- Trial name
- NCT02905565
- Testing
- NBP Softgel Capsules
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
Stroke, Stroke, Acute
The Safety and Effectiveness of CVA-FLOW Software Device for Acute Ischemic Stroke
The purpose of this study is to demonstrate the effectiveness and safety of CVA-FLOW, a digital health AI based Telestroke system developed by CVAID Ltd.
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Cardiovascular
- Trial name
- NCT05745051
- Testing
- CVAid Flow
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Cvaid Medical
Acute Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24A (NCT03767192)
- Testing
- Active Stimulation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 327 people
- Sponsor
- BrainsGate
Acute Ischemic Stroke
First-in-man Study of the Cerebrovascular Interventional Procedural Control System
The objective of this study the first human use of a new device in treatment of acute ischemic stroke, which to evaluate the feasibility, safety, and efficacy of the Cerebrovascular Interventional Procedural Control System.
- Trial name
- NCT05972252
- Testing
- Cerebrovascular Interventional Procedural Control System
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Dinova Neuroscience Technology Co., Ltd